XML 86 R75.htm IDEA: XBRL DOCUMENT v3.24.3
Revenue Arrangements - Narrative (Details) - USD ($)
 1 Months Ended 3 Months Ended 9 Months Ended
Jun. 28, 2024
Jan. 31, 2023
Oct. 31, 2021
Jun. 30, 2020
Sep. 30, 2024
Sep. 30, 2023
Jun. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Jun. 30, 2024
Dec. 31, 2023
Disaggregation of Revenue [Line Items]                      
Deferred revenue related to agreement         $ 0     $ 0     $ 5,849,000
Deferred revenue         0     0     2,311,000
Deferred revenue, net of current portion         0     0     3,538,000
Accounts receivable         4,829,000     4,829,000     5,870,000
Revenue recognized               (5,849,000)      
Collaboration and license revenue         0 $ 6,551,000   39,111,000 $ 17,738,000    
Remaining performance obligation         0     0      
Grant revenue         387,000 0   561,000 0    
National Institute of Neurological Disorders and Stroke of the National Institutes of Health Funding                      
Disaggregation of Revenue [Line Items]                      
Government assistance, award amount                   $ 1,500,000  
Government assistance, potential additional award amount                   $ 1,500,000  
Government assistance, asset, current         600,000     600,000      
Grant revenue         400,000     600,000      
SOBI Purchase Agreement                      
Disaggregation of Revenue [Line Items]                      
Accounts receivable         4,200,000     4,200,000     4,600,000
Collaboration and license revenue         0 5,000,000   32,800,000 13,700,000    
SOBI Purchase Agreement | Billed Revenues                      
Disaggregation of Revenue [Line Items]                      
Accounts receivable         1,000,000.0     1,000,000.0     3,000,000.0
Takeda Agreement                      
Disaggregation of Revenue [Line Items]                      
Deferred revenue         0     0     0
Upfront cash payment     $ 3,000,000                
Future additional payments, expected     $ 1,124,000,000                
Milestone payments             $ 500,000        
Customer, liability, revenue recognized, including opening balance         0 0   0 600,000    
Collaborative Arrangement | SOBI Purchase Agreement                      
Disaggregation of Revenue [Line Items]                      
Upfront cash payment       $ 75,000,000              
Sales milestone payments       $ 630,000,000              
Revenue recognized $ 30,000,000             30,000,000      
Astellas Gene Therapies                      
Disaggregation of Revenue [Line Items]                      
Upfront payment   $ 10,000,000                  
Development and commercial milestones plus royalties   $ 340,000,000                  
Deferred revenue related to agreement         0     0      
Deferred revenue                     2,300,000
Deferred revenue, net of current portion                     3,500,000
Accounts receivable         100,000     100,000     $ 300,000
Revenue recognized         0 1,500,000   6,300,000 2,900,000    
Revenue, remaining performance obligation recognized               3,200,000      
Sarepta Therapeutics, Inc.                      
Disaggregation of Revenue [Line Items]                      
Revenue recognized         $ 0 $ 0   $ 0 $ 500,000    
Option term       24 months